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Abstract: Background: Cross-sectional studies have reported a lower prevalence of sensitisation in 
older adults, but few longitudinal studies have examined whether this is an aging or a year-of-birth 
cohort effect. 
Objective: To assess changes in sensitisation and total IgE in a cohort of European adults as they aged 
over 20-year period. 
Methods: Serum specific IgE to common aeroallergens (house dust mite, cat, grass) and total IgE were 
measured in 3206 adults, from 25 centres in the European Community Respiratory Health Survey, on 
three occasions over 20 years. Changes in sensitisation and total IgE were analysed by regression 
analysis, corrected for potential differences in laboratory equipment, and using inverse sampling-
probability weights to account for non-response. 
Results: Over the 20-year follow-up, the prevalence of sensitisation to at least one of the three 
allergens fell from 29.4% to 24.8% (-4.6%, 95%CI: -7.0% to -2.1%). The prevalence of sensitisation to 
house dust mite (-4.3%, 95%CI: -6.0% to -2.6%) and cat (-2.1%, 95%CI: -3.6% to -0.7%) fell more than 
sensitisation to grass (-0.6%, 95%CI: -2.5% to 1.3%). Age-specific prevalence of sensitisation to house 
dust mite and cat did not differ between year-of-birth cohorts, but sensitisation to grass was most 
prevalent in the most recent ones. Overall, total IgE fell significantly (geometric mean ratio: 0.63, 
95%CI 0.58 to 0.68), at all ages, in all year-of-birth cohorts. 
Conclusion: While there was evidence that aging was associated with lower levels of sensitisation to 
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Background: Cross-sectional studies have reported a lower prevalence of sensitisation in 145 
older adults, but few longitudinal studies have examined whether this is an aging or a year-of-146 
birth cohort effect. 147 
Objective: To assess changes in sensitisation and total IgE in a cohort of European adults as 148 
they aged over 20-year period. 149 
Methods: Serum specific IgE to common aeroallergens (house dust mite, cat, grass) and total 150 
IgE were measured in 3206 adults, from 25 centres in the European Community Respiratory 151 
Health Survey, on three occasions over 20 years. Changes in sensitisation and total IgE were 152 
analysed by regression analysis, corrected for potential differences in laboratory equipment, 153 
and using inverse sampling-probability weights to account for non-response. 154 
Results: Over the 20-year follow-up, the prevalence of sensitisation to at least one of the 155 
three allergens fell from 29.4% to 24.8% (-4.6%, 95%CI: -7.0% to -2.1%). The prevalence of 156 
sensitisation to house dust mite (-4.3%, 95%CI: -6.0% to -2.6%) and cat (-2.1%, 95%CI: -157 
3.6% to -0.7%) fell more than sensitisation to grass (-0.6%, 95%CI: -2.5% to 1.3%). Age-158 
specific prevalence of sensitisation to house dust mite and cat did not differ between year-of-159 
birth cohorts, but sensitisation to grass was most prevalent in the most recent ones. Overall, 160 
total IgE fell significantly (geometric mean ratio: 0.63, 95%CI 0.58 to 0.68), at all ages, in all 161 
year-of-birth cohorts. 162 
Conclusion: While there was evidence that aging was associated with lower levels of 163 
sensitisation to house dust mite and cat, this was not observed for sensitisation to grass. 164 
   165 
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Key messages 166 
 In a multinational population-based cohort of adults there was a fall in IgE 167 
sensitization to house dust mite and cat, but not grass, as the cohort aged over 20 168 
years. Total IgE also fell as the cohort aged. 169 
 The fall in IgE sensitization seemed stronger after 40 years of age. 170 
 171 
Capsule summary 172 
After following a large multinational population-based cohort over 20 years, we show that the 173 
lower prevalence of IgE sensitisation in older adults is explained by aging. 174 
 175 
Key words 176 
Allergens; sensitisation; cohort study; epidemiology; immunoglobulin E; longitudinal 177 
analysis; aging; immunosenescence 178 
  179 
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Population-based cross-sectional studies have shown that the prevalence of sensitisation is 180 
higher in younger than in older age groups (1-4). Although there have been year-of-birth 181 
cohort-related increases in atopy over the last decades, it is hypothesised that these cross-182 
sectional observations may, in addition, reflect decreases in sensitisation with aging-related 183 
immunosenescence. Longitudinal studies that have performed skin prick tests or measured 184 
serum allergen specific IgE, at baseline and follow-up over periods of up to 14 years, have 185 
reported that sensitisation increased with aging, although changes were less evident in 186 
middle-aged and older adults (2, 5-7). Two recent longitudinal studies reported no change or 187 
a slight decline in sensitisation with aging (4, 8). In one of these studies, changes in 188 
sensitisation were based on allergen specific IgE measures (8), while in the other the 189 
comparison between time points was based on both specific IgE and skin prick tests (4).  190 
Within the European Community Respiratory Health Survey (ECRHS) (9), a multicentre 191 
cohort study of over 6000 young and middle aged adults followed for a 10-year period, there 192 
was little evidence of substantial change in sensitisation to at least one of cat, grass or house 193 
dust mite (as measured by serum specific IgE) over time as the cohort aged.  The age-specific 194 
prevalence of sensitisation to grass, but not to the other allergens measured, was higher in 195 
more recent year-of-birth cohorts. At the time, it was observed that changes in laboratory 196 
methods between the baseline and follow-up could influence assessment of change in 197 
sensitisation – such biases are even more difficult to quantify when using skin prick tests.  198 
Completion of the third phase of the ECRHS has allowed assessment of serum specific IgE 199 
on three occasions: at baseline, ten-year and twenty-year follow-up. The aims of this report 200 
were to: 1) to assess the changes in IgE sensitisation and in total IgE in this population-based 201 
cohort of European adults over a period of 20 years; and 2) to investigate whether these 202 





Study participants 206 
This is a multicentre population-based cohort study. Detailed descriptions of the methods for 207 
ECRHS I and ECRHS II have been published elsewhere (10, 11). In ECRHS I, 1500 men and 208 
1500 women age 20 to 44 years were randomly recruited from community-based sampling 209 
frames in each centre. After completing a short postal screening questionnaire, a random 210 
sample of responders was selected to complete an interviewer-led questionnaire and provided 211 
a blood sample (1991-1993). In the majority of centres, an additional sample of people with 212 
symptoms highly suggestive of asthma were recruited for study, but these participants are not 213 
included in the present analysis. 214 
In ECRHS II (1998-2002), participants who had completed the extended questionnaire in 215 
ECRHS I were re-investigated, and again provided a blood sample. In ECRHS III, those who 216 
took part in the clinical stages of ECRHS I and II were again contacted, with responders 217 
invited to a local testing centre where, once more, blood samples were taken (2008-2013). 218 
Eleven countries are represented in this report: Iceland (Reykjavik), Norway (Bergen), 219 
Sweden (Gothenburg, Umeå, and Uppsala), Estonia (Tartu), Belgium (Antwerp South, and 220 
Antwerp City), Germany (Hamburg, and Erfurt), UK (Ipswich, and Norwich), France 221 
(Bordeaux, Grenoble, Montpelier, and Paris), Spain (Barcelona, Galdakao, Albacete, Oviedo, 222 
and Huelva), Italy (Pavia, Turin, and Verona), and Australia (Melbourne). 223 
Ethical approval for the study from local research ethics committees and written consent from 224 
participants were obtained. 225 
 226 
Measurement of IgE 227 
In all three surveys, blood samples were obtained and processed under similar conditions. 228 
After clotting and centrifuging, serum was stored at -20 °C until analysis in a single central 229 
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laboratory (Pharmacia Uppsala in 1992, Kings College London in 2002, and AMC 230 
Amsterdam in 2013/2014) using the Phadia ImmunoCAP system (now Thermo Fisher 231 
Scientific, Uppsala, Sweden). 232 
To assess the effects of potential laboratory bias on prevalence of IgE sensitisation and mean 233 
of total IgE estimates, we conducted duplicate assays on 794 samples (tested at ECRHS I, 234 
stored, and tested at ECRHS II) and 475 samples (tested at ECRHS II, stored, and tested at 235 
ECRHS III) (online table 1). The methods for this correction are described in detail in the 236 
online supplement. 237 
 238 
Outcomes 239 
Participants were considered to be sensitised if allergen specific IgE to Dermatophagoides 240 
pteronyssinus (house dust mite), Felis silvestris catus (cat), and Phleum pratense (Timothy 241 
grass) was present in concentrations >0.35 kUA/L. A higher threshold (>0.70 kUA/L) was also 242 
considered. ‘Atopy’ was defined as being sensitised to one of either house dust mite, grass or 243 
cat. Total IgE, expressed in kilounits/litre (kU/L), was log-transformed and considered as a 244 
continuous outcome for estimation of geometric means and their ratios.  245 
 246 
Statistical methods 247 
Statistical analyses were performed using Stata V.13 (StataCorp LP, College Station, TX).  248 
Analyses were restricted to the 3206 participants with information on serum specific IgE and 249 
total IgE in all three ECRHS surveys (Figure 1). Inverse sampling-probability weights were 250 
used to standardise the estimation from this population with data on IgE assays from all three 251 
ECRHS surveys to the original target population of participants with data on IgE assays from 252 




The prevalence of sensitisation at each survey was determined using logistic regression with 255 
Huber variances considering participants as the clusters. Confidence intervals for 256 
prevalences, and their differences (net change) between ECRHS II and I, ECRHS III and II, 257 
and ECRHS III and I were estimated using the normalising hyperbolic-arctangent 258 
transformation (12). Similarly, using linear regression, we calculated geometric mean (GM) 259 
ratios of total IgE between ECRHS II and I, ECRHS III and II, and ECRHS III and I. We 260 
used the margins and nlcom commands in Stata to do this and the regpar add-on 261 
package (13) as required. 262 
Statistical analyses for each outcome were performed in two ways, using uncorrected models 263 
and models corrected for potential laboratory bias. Only results of the corrected models are 264 
presented in this report. As data came from multiple centres, we tested for between-centre 265 
heterogeneity in the uncorrected results using the methods of Cochran (14). 266 
In a final step, analyses were repeated: 1) stratified by gender; 2) restricted to lifetime non-267 
smokers; and c) by year-of-birth cohort. For this latter step, year-of-birth cohorts were 268 
defined by date of birth (1964-1973, 1954-1963, 1944-1953). The ages of these participants 269 
at 1 January 1992 (the approximate midpoint of ECRHS I data collection) would have been 270 
18≤age<28, 28≤age<38 and 38≤age≤48 years, respectively (participants from Tartu, Estonia, 271 
were recruited aged 20-44 in 1994 and would have been less than 20 years on 1 January 272 
1992, hence 18 years is the lower age limit). Members of each age cohort would have been 273 
10 years older on 1 January 2002 (during the ECRHS II data collection) and 20 years older 274 
on 1 January 2012 (during the ECRHS III data collection). This approach allowed 275 




A total of 3206 (30.6%) of the 10,478 participants who provided a blood sample in the first 278 
survey took part and again provided a sample in both ECRHS II and III. The median age of 279 
participants at ECRHS I was 34.9 years (interquartile range: 28.6-40.5), half were males, and 280 
forty five percent were lifetime non-smokers. There was variation between centres in the 281 
proportion of participants who provided samples at ECRHS I and then went on to provide 282 
samples at ECRHS II and ECRHS III (minimum: 13.6% in Pavia; maximum: 58.6% in 283 
Reykjavik). Factors associated with response were older age, and being a non-smoker. 284 
Response was not associated with sensitisation at baseline, gender, and reporting of wheeze 285 
(online table 2), although those who took part in all three surveys did report waking with 286 
breathlessness less frequently. 287 
 288 
Net change in IgE sensitisation and total IgE 289 
Laboratory-corrected net changes in prevalence of IgE sensitisation to each of the allergens 290 
and in geometric mean of total IgE over a period of 20 years are shown in table 1. Between 291 
ECRHS I and ECRHS II there was no significant change in the prevalence of IgE 292 
sensitisation to any of the allergens using either the low or the high cut-off levels.  293 
Over the 20 years of follow up, i.e. between ECRHS I and ECRHS III, prevalence of IgE 294 
sensitisation to house dust mite, cat, and to at least one allergen fell. Using the 0.35 kUA/L 295 
cut-off, the prevalence of sensitisation to grass remained stable, but when the 0.70 kUA/L cut-296 
off was used there was evidence of a reduction in sensitisation. These changes were similar in 297 
men and women (online table 3). 298 
For some estimates there was evidence of heterogeneity between countries, but no clear 299 
pattern by latitude (figure 2) or response rate (online figure 1) in this variation was observed.  300 
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Overall there was a significant fall in total IgE over the 20 years of follow up (geometric 301 
mean ratio: 0.63, 95% CI 0.58 to 0.68). This generalised fall in total IgE occurred in all 302 
centres, although the magnitude of the change varied (heterogeneity between centres P < 303 
0.001; online figure 2). Patterns were similar in men and women (online table 3). 304 
Restriction of analyses to the 1304 participants who were lifetime non-smokers did not 305 
materially alter the results reported above (online table 4). 306 
 307 
Association of net change with age and cohort 308 
In ECRHS I, the prevalence of IgE sensitisation to house dust mite, grass, cat, and to at least 309 
one allergen was higher in younger adults (i.e. those born more recently) than in older adults 310 
(table 2). 311 
Over the 20-year period, the prevalence of sensitisation to house dust mite fell in all age 312 
groups to a similar extent, and there was little evidence that the age-specific prevalence of 313 
sensitisation to house dust mite was different between those born more recently and those 314 
born earlier (figure 3A). Overall the picture was one of a decrease in sensitisation with age, 315 
with decreases occurring throughout adult life. This was broadly similar for sensitisation to 316 
cat (figure 3C). However, these patterns were different for sensitisation to grass. Although 317 
there was evidence of a fall in sensitisation to grass in those who were the oldest at 318 
recruitment (i.e. the earlier cohort), falls were not seen in those who were born more recently. 319 
As a result, there were marked differences in the age-specific prevalence of sensitisation to 320 
grass between cohorts with higher age-specific prevalence in those born after 1964 (figure 321 
3B). The prevalence of IgE sensitisation to at least one of house dust mite, grass and cat 322 
showed a pattern similar to that of sensitisation to house dust mite and cat. The most recent 323 
cohort had the highest prevalence at younger ages, but these cohort-related differences were 324 
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not apparent in later adult life (figure 3D). Similar patterns were observed when using the 325 
cut-off of 0.70 kUA/L (online table 5). 326 
The population GM of total IgE was lower at each follow up, in all cohorts over the 20-year 327 
period of follow up, and the more recent cohorts had lower levels of total IgE than those born 328 
earlier at the equivalent ages (figure 4, table 2). 329 




We have shown that the prevalence of sensitisation to at least one of house dust mite, cat or 332 
grass has decreased within a large population-based adult cohort followed over a period of 20 333 
years. There was a decrease in the prevalence of sensitisation to house dust mite, and to cat, 334 
and the geometric mean total IgE levels also decreased. Sensitisation to grass did not follow 335 
these patterns so clearly, showing, instead, an increase in younger ages and aging effects only 336 
at older ages. 337 
Strengths of this study are the population-based nature of the sample derived from several 338 
parts of Europe and Australia, the prolonged period of follow-up and the standardised 339 
handling and testing of samples between centres and over time. Changes in laboratory staff, 340 
consumables and methods between surveys could lead to bias in prevalence estimates and to 341 
address this we have used information from duplicate assays of hundreds of samples to adjust 342 
our estimates. As with all cohorts, there has been attrition during the 20-year period of 343 
follow-up and the analyses we present are based on participants who have taken part in all 344 
three phases of the study. We are aware that considerable loss to follow up has the potential 345 
to induce bias, therefore to account for small differences between these individuals and the 346 
initial cohort at baseline and to enhance the external validity of our results, we have corrected 347 
our models with inverse sampling-probability weights. This method generates estimates that 348 
apply to the population we sampled at baseline.  349 
To date, few other population-based studies have reported on longitudinal changes in 350 
sensitisation by measuring serum specific IgE levels (6, 8). These earlier reports, both in 351 
Denmark, are on smaller samples and mostly over shorter time periods. Linneberg et al. 352 
studied changes over an 8-year period in serum specific IgE to at least one of six allergens in 353 
about 400 adolescents and adults in Copenhagen (6), reporting an increase in prevalence of 354 
IgE sensitisation, especially among those born in the 1960s or later. Older adults (above 40 355 
17 
 
years, n = 695) living in the same city and followed for 20 years showed no change in 356 
sensitisation over a 20-year period in prevalence of IgE sensitisation to at least one of 19 357 
allergens (8). Other studies looked at changes in sensitisation by performing skin prick tests 358 
and reported increases with aging (2, 4, 5). However, skin prick tests are much more difficult 359 
to standardise over different periods as they are prone to fieldworker variation, with changes 360 
in skin prick test reagents being difficult to assess (15, 16). 361 
Barbee et al. studied 1100 participants in the US and reported a decrease in levels of total IgE 362 
with age in children and young adults, but not in older adults (17). In the ECRHS, total IgE 363 
levels fell with aging within each cohort, with more recent cohorts having lower levels of 364 
total IgE than earlier ones at the same age. In a previous report, we showed that smoking 365 
associated differently with sensitisation to different aeroallergens, and in a dose-response 366 
manner with total IgE levels (18). Therefore, we hypothesized that changes in sensitisation 367 
over time could be related to declining smoking rates and that lifetime non-smokers would 368 
not show changes in sensitisation. Our present findings show that a decline in sensitisation is 369 
unlikely to be related to smoking cessation. The fall in total IgE in our study may in part be 370 
explained by a decline in helminthic infestation as observed by others in children (19). 371 
We saw no evidence of change in the prevalence of IgE sensitisation to house dust mite, cat, 372 
grass, and at least one of these three as the cohort aged over the initial 10 years of follow-up 373 
of the ECRHS (9). This observation is confirmed within this second report, but we go on to 374 
show that prevalence does decrease over 20 years, and appears greater when people are aged 375 
about 40 or older. This finding may be explained by immunosenescence, which seems to be 376 
more evident after 50 years of age (20) and corresponds to age-related changes in the number 377 
and function of cells from the immune system (21). The production of IgE, which is 378 
dependent on an interaction between B cells and T cells (22), may decline as a consequence 379 
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of the naturally occurring involution of the thymus (23) – the thymic output of T cells per day 380 
in a 50-year old is about 33% lower than that of a 25-year old (23). 381 
Our findings are supported by animal studies, which suggest that the production of IgE to an 382 
allergen challenge is higher in younger than older animals (24, 25). In one of these studies, 383 
the transplant of thymocytes into young (8 weeks old) mice resulted in no change in IgE 384 
response, whereas that into aged (65 weeks old) mice resulted in an enhanced IgE response 385 
similar to that of young mice (25). 386 
One might expect all markers of atopy to follow similar age/period/cohort patterns. Our 387 
report suggests grass may be different to house dust mites and cat, but we can only speculate 388 
as to the reason for this. There are differences in the epidemiology of each, particularly with 389 
respect to factors associated with the ’hygiene hypothesis’. Larger sibships protect younger 390 
siblings from hay fever and from sensitisation to grass more strongly than from asthma and 391 
sensitisation to house dust mites (26, 27). Declining family size over the last decades may 392 
explain the less marked aging effect for grass than for other allergens. Changes in the level of 393 
exposure to pollens may have had a role in our findings (28, 29). There are also reports 394 
suggesting that pollens in our more modern society are more allergenic than they have been 395 
previously (30, 31), which could be related to the high levels of air pollutants such as ozone, 396 
nitrogen dioxide and carbon dioxide (31-33). The presence of unmeasured factors may also 397 
have a role in the different patterns observed in the sensitisation to the three allergens. 398 
In summary, over a period of 20 years the prevalence of specific IgE sensitisation to house 399 
dust mite and cat, but not grass, significantly fell in the multinational cohort of adults from 400 
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ECRHS II vs I 




ECRHS III vs I 
P for heterogeneity 
between centres 
House dust mite      
(>0.35 kUA/L) 16.6 -0.7 
(-2.2 to 0.9) 
0.051 -4.3 
(-6.0 to -2.6) 
0.71 
(>0.70 kUA/L) 13.1 -0.7 
(-1.9 to 0.4) 
0.63 -3.1 
(-4.5 to -1.7) 
0.21 
Grass      
(>0.35 kUA/L) 17.0 0.5 
(-1.0 to 2.0) 
0.048 -0.6 
(-2.5 to 1.3) 
0.009 
(>0.70 kUA/L) 14.2 0.0 
(-1.3 to 1.3) 
0.48 -2.2 
(-3.8 to -0.6) 
0.97 
Cat      
(>0.35 kUA/L) 8.8 -0.9 
(-2.1 to 0.3) 
0.14 -2.1 
(-3.6 to -0.7) 
0.09 
(>0.70 kUA/L) 6.4 0.0 
(-1.0 to 1.1) 
0.15 -1.1 
(-2.2 to 0.1) 
0.04 
House dust mite 
or grass or cat 
     
(>0.35 kUA/L) 29.4 0.1 
(-2.0 to 2.1) 
0.003 -4.6 
(-7.0 to -2.1) 
0.03 
(>0.70 kUA/L) 24.2 -0.6 
(-2.2 to 1.0) 
0.11 -4.6 
(-6.6 to -2.6) 
0.17 





ECRHS II vs I 
P for heterogeneity 
between centres 
GM ratio 
 (95% CI) 
ECRHS III vs I 





(0.78 to 0.90) 
< 0.001 0.63 
(0.58 to 0.68) 
< 0.001 




Table 2. Net change in IgE sensitisation (>0.35 kUA/L) to house dust mite, grass, and cat, and total IgE (kU/L) over 20 years, by year-of-birth 
cohort. 
















II vs I 
ECRHS 




II vs I 
ECRHS 




II vs I 
ECRHS 
III vs I 
House dust mite 
 
18.6 -0.6 
(-3.0 to 1.8) 
-4.1 
(-6.7 to -1.5) 
17.2 0.2 
(-1.9 to 2.4) 
-4.5 
(-6.9 to -2.1) 
13.8 -2.0 
(-3.9 to -0.1) 
-4.3 




(0.4 to 6.2) 
1.5 
(-1.8 to 4.9) 
15.9 0.5 
(-1.4 to 2.3) 
-0.1 
(-2.5 to 2.3) 
15.4 -1.9 
(-3.8 to 0.0) 
-3.2 




(-2.2 to 2.6) 
-0.7 
(-3.5 to 2.0) 
8.3 -1.4 
(-2.9 to 0.1) 
-2.0 
(-3.6 to -0.3) 
8.1 -1.2 
(-2.7 to 0.2) 
-3.6 
(-5.2 to -2.0) 
House dust mite or grass 
or cat  
33.5 1.9 
(-1.3 to 5.1) 
-2.1 
(-6.1 to 1.9) 
28.7 1.1 
(-1.6 to 3.7) 
-4.1 
(-7.2 to -1.1) 
26.5 -3.0 
(-5.6 to -0.3) 
-7.4 
(-10.4 to -4.3) 
Total IgE 29.9 0.81 
(0.72 to 0.91) 
0.61 
(0.54 to 0.68) 
31.3 0.85 
(0.78 to 0.92) 
0.61 
(0.56 to 0.67) 
27.9 0.84 
(0.78 to 0.92) 
0.68 
(0.61 to 0.75) 





Figure 1. Participant flow in the European Community Respiratory Health Survey (only 
centres that took part in all three surveys are included). 
 
Figure 2. Net change in prevalence of IgE sensitisation (cut-off: 0.35 kUA/L) to house dust 
mite [(I
2 
(heterogeneity) = 0.0%, P = 0.71)], grass (I
2
 = 44.9%, P = 0.009), cat (I
2
 = 29.0%, P 
= 0.09), and at least one of these allergens (I
2
 = 38.6%, P = 0.03). Centres are sorted by 
latitude (from North to South). 
 
Figure 3. Prevalence of IgE sensitisation to (A) house dust mite, (B) grass, (C) cat, and (D) at 
least one of these three allergens, over 20 years of follow up, by year-of-birth cohort. 
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Online methods 1 
Statistical analyses were performed using Stata V.13 (StataCorp LP, College Station, TX).  2 
 3 
Laboratory bias (duplicate measurements) 4 
To assess the effects of potential laboratory bias on prevalence of IgE sensitisation and mean 5 
of total IgE estimates, we conducted duplicate assays on 794 samples (tested at ECRHS I, 6 
stored, and tested at ECRHS II) and 475 samples (tested at ECRHS II, stored, and tested at 7 
ECRHS III). Confidence intervals for Cohen’s kappa statistics for each comparison between 8 
two measurements of the same sample were computed using the kap command in Stata, 9 
together with delta-method standard errors, using the normalising and variance-stabilising 10 
transformation ln(1-kappa) (online table 1). 11 
 12 
Elimination of laboratory bias 13 
To correct our estimates for laboratory bias, we included in the models: 14 
- the three main-assessment assays for each participant (GMs or odds for each 15 
combination of centre and ECRHS survey); 16 
- four extra parameters (GM ratios or odds ratios) regarding the paired method-17 
comparison assays: 18 
o two indicating an assay’s membership in the two method-comparison studies; 19 
o two indicating that an assay was carried out using the method of ECRHS II or 20 








Inverse sampling-probability weighted estimation 26 
Inverse sampling-probability weights were used to standardise the estimation from the 27 
population with data on IgE assays in all three ECRHS surveys to a target population of 28 
participants with data on IgE assays from ECRHS I, which was randomly sampled from the 29 
general adult population in different European and Australian centres. 30 
 31 
The inverse sampling-probability weights were calculated using a logistic regression model 32 
(1) with a separate set of parameters for each centre with any IgE data responders, predicting 33 
response to all three surveys from baseline characteristics, adapted from the response-34 
regression model of Jarvis et al. (2). The parameters for each centre were a baseline odds, an 35 
exponential per-decade odds ratio for age at 01 January 1992, an odds ratio for female gender 36 
(compared to a baseline of male gender), odds ratios for self-reported smoking status at 37 
ECRHS I (‘ex’ and ‘current’ compared to a baseline of ‘never’), an odds ratio for wheeze at 38 
ECRHS I, an odds ratio for waking with shortness of breath at ECRHS I, and an odds ratio 39 
for IgE sensitisation to house dust mite, cat, or grass at ECRHS I. When we meta-analysed 40 
the parameters using randomly-variable-effects meta-analysis (3), we found that participants 41 
who have taken part in all three phases of the study were slightly older, less likely to be 42 
smokers and less likely to have reported shortness of breath than participants who did not 43 
have serum IgE in all three surveys (online table 2). 44 
 45 
The use of inverse sampling-probability weights to standardise the estimates to the target 46 
population in ECRHS I seemed to work, as indicated by a Somers’ D of response-propensity 47 
score (4) with respect to response of 0.008 when inverse sampling-probability weighted 48 
versus one of 0.239 when unweighted. 49 




1. Robins JM, et al. Estimation of regression coefficients when some regressors are not 52 
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1986;7:177-88. 57 
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2002 vs 1992 
(95% CI) 
Cohen kappa 








2013/14 vs 2002 
(95% CI) 
Cohen kappa 
2013/14 vs 2002 











% N = 475 
House dust mite 
(0.35 kUA/L) 
241 30.4 247 31.1 
0.8 
(-1.3 to 2.8) 
0.80 
 
129 27.2 133 28.0 
0.8 
(-0.6 to 2.3) 
0.94 
(0.70 kUA/L) 193 24.3 195 24.6 
0.3 
(-1.1 to 1.6) 
0.89 
 
106 22.3 104 21.9 
-0.4 




229 28.8 224 28.2 
-0.6 
(-2.3 to 1.1) 
0.86 
 
119 25.1 115 24.2 
-0.8 
(-2.1 to 0.5) 
0.94 
(0.70 kUA/L) 187 23.6 196 24.7 
1.1 
(-0.3 to 2.6) 
0.88 
 
99 20.8 98 20.6 
-0.2 




116 14.6 133 16.8 
2.1 
(0.7 to 3.6) 
0.83 
 
60 12.6 63 13.3 
0.6 
(-0.7 to 2.0) 
0.90 
(0.70 kUA/L) 94 11.8 102 12.8 
1.0 
(-0.3 to 2.3) 
0.85 
 
51 10.7 54 11.4 
0.6 
(-0.5 to 1.7) 
0.92 
Sensitisation to 
at least one 
allergen 
(0.35 kUA/L) 
336 42.3 338 42.6 
0.3 
(-1.8 to 2.3) 
0.82 
 
182 38.3 186 39.2 
0.8 
(-0.9 to 2.6) 
0.92 
(0.70 kUA/L) 278 35.0 293 36.9 
1.9 
(0.4 to 3.4) 
0.89 
 
159 33.5 162 34.1 
0.6 
(-0.7 to 2.0) 
0.95 
              
 GM in 1992 
N = 794 
GM in 2002 
N = 794 
GM ratio 2002 vs 1992 
(95% CI) 
 GM in 2002 
N = 475 
GM in 2013/14 
N = 475 











GM, Geometric mean. 
  
Online tables 1-5
Click here to download Rep sitory E Tables: Online tables_10A r2015.docx
Online table 2. Baseline characteristics of subjects with IgE measurements in all three surveys of ECRHS versus subjects with IgE measurements in baseline survey 
only from same centres. 




(n = 7272) 
With IgE 
measurements 
in all three 
surveys 
(n = 3206) 
Adjusted* odds 
for responding 
(95% CI) P for heterogeneity# 
Age at baseline (per 10 years) - - 1.40 (1.29-1.52) 0.036 
Female (%) 49.9 50.0 1.00 (0.19-1.11) 0.17 
Smoking status at baseline (%)     
Lifetime non-smoker 41.6 45.1 1.00  
Ex-smoker 21.1 22.6 0.88 (0.78-1.01) 0.29 
Current smoker 37.3 32.3 0.65 (0.58-0.73) 0.38 
Symptoms in the last 12 months     
Wheeze 22.2 19.8 0.97 (0.84-1.11) 0.12 
Woken with shortness of breath 6.4 4.8 0.76 (0.61-0.94) 0.40 
Sensitised to at least one allergen** (%) 29.5 27.9 1.05 (0.91-1.22) 0.0017 
*From meta-analysis by centre, adjusting for all other factors in table. 
**House dust mite, cat, grass. 
#From random effects meta-analysis. 
  
Online table 3. Net change in IgE sensitisation to house dust mite, grass, and cat, and total IgE over 20 years, by gender. 









































           
(>0.35 kUA/L) 19.7 -0.5 
(-2.7 to 1.6) 
0.20 -5.0 
(-7.2 to -2.8) 
0.59  13.5 -0.8 
(-2.5 to 0.9) 
0.038 -3.7 
(-5.7 to -1.7) 
0.34 
(>0.70 kUA/L) 15.1 -0.3 
(-2.0 to 1.4) 
0.95 -2.9 
(-4.9 to -0.9) 
0.26  11.0 -1.1 
(-2.3 to 0.1) 
0.096 -3.3 
(-5.0 to -1.6) 
0.057 
Grass            
(>0.35 kUA/L) 18.5 0.4 
(-1.6 to 2.4) 
0.18 -0.9 
(-3.2 to 1.3) 
0.11  15.6 0.6 
(-1.2 to 2.4) 
0.94 -0.2 
(-2.5 to 2.1) 
0.74 
(>0.70 kUA/L) 15.8 -0.3 
(-2.0 to 1.5) 
0.16 -3.1 
(-5.1 to -1.0) 
0.82  12.7 0.3 
(-1.2 to 1.8) 
0.91 -1.3 
(-3.3 to 0.6) 
0.95 
Cat            
(>0.35 kUA/L) 8.7 -0.3 
(-1.9 to 1.3) 
0.21 -2.1 
(-3.8 to -0.4) 
0.40  8.9 -1.5 
(-2.9 to -0.1) 
0.54 -2.2 
(-3.9 to -0.5) 
0.074 
(>0.70 kUA/L) 6.4 0.2 
(-1.2 to 1.6) 
0.22 -1.2 
(-2.7 to 0.3) 
0.27  6.4 -0.1 
(-1.4 to 1.1) 
0.071 -1.0 
(-2.3 to 0.4) 
0.013 
House dust 
mite or grass 
or cat 
           
(>0.35 kUA/L) 32.5 0.8 
(-1.8 to 3.5) 
0.74 -5.6 
(-8.6 to -2.5) 
0.39  26.2 -0.7 
(-3.0 to 1.6) 
0.46 -3.6 
(-6.4 to -0.7) 
0.089 
(>0.70 kUA/L) 26.5 0.3 
(-2.0 to 2.5) 
0.81 -4.6 
(-7.2 to -2.0) 
0.25  21.9 -1.5 
(-3.2 to 0.3) 
0.40 -4.5 
(-6.8 to -2.2) 
0.056 












 (95% CI) 
ECRHS 
















 (95% CI) 
ECRHS 








(0.75 to 0.88) 
< 0.001 0.65 
(0.59 to 0.71) 
< 0.001  26.0 0.86 
(0.79 to 0.93) 
0.004 0.61 
(0.56 to 0.67) 
< 0.001 










ECRHS II vs I 




ECRHS III vs I 
P for heterogeneity 
between centres 
House dust mite      
(>0.35 kUA/L) 15.8 0.0 
(-1.9 to 2.0) 
0.005 -3.4 
(-5.5 to -1.4) 
0.08 
(>0.70 kUA/L) 12.4 -0.9 
(-2.2 to 0.5) 
0.79 -2.0 
(-3.8 to -0.2) 
0.41 
Grass      
(>0.35 kUA/L) 20.5 1.1 
(-1.0 to 3.3) 
0.75 -0.4 
(-3.0 to 2.2) 
0.26 
(>0.70 kUA/L) 17.9 0.2 
(-1.6 to 2.1) 
0.65 -2.5 
(-4.9 to -0.1) 
0.98 
Cat      
(>0.35 kUA/L) 10.5 -0.6 
(-2.3 to 1.1) 
0.78 -2.0 
(-4.1 to 0.0) 
0.42 
(>0.70 kUA/L) 8.0 0.4 
(-1.2 to 2.0) 
0.71 -0.8 
(-2.5 to 1.0) 
0.42 
House dust mite 
or grass or cat 
     
(>0.35 kUA/L) 31.4 1.9 
(-0.8 to 4.5) 
0.002 -2.9 
(-6.0 to 0.2) 
0.03 
(>0.70 kUA/L) 26.7 0.1 
(-1.9 to 2.2) 
0.21 -3.3 
(-5.9 to -0.6) 
0.21 





ECRHS II vs I 
P for heterogeneity 
between centres 
GM ratio 
 (95% CI) 
ECRHS III vs I 





(0.75 to 0.89) 
< 0.001 0.62 
(0.56 to 0.68) 
< 0.001 
GM, Geometric mean. 
  
Online table 5. Net change in IgE sensitisation (>0.70 kUA/L) to house dust mite, grass, and cat over 20 years, by birth cohort. 
 1964-1973 (N = 736) 
Net change (95% CI) 
1954-1963 (N = 1314) 
Net change (95% CI) 
1944-1953 (N = 1156) 
















II vs I 
ECRHS 




II vs I 
ECRHS 




II vs I 
ECRHS 
III vs I 
House dust mite 
 
15.0 0.3 
(-1.9 to 2.4) 
-1.5 
(-4.2 to 1.2) 
14.1 -0.9 
(-2.6 to 0.8) 
-4.4 
(-6.4 to -2.4) 
9.9 -1.3 
(-2.7 to 0.0) 
-2.7 




(-0.8 to 4.2) 
-0.7 
(-3.7 to 2.4) 
13.8 0.1 
(-1.6 to 1.7) 
-2.2 
(-4.3 to -0.2) 
11.4 -1.6 
(-3.2 to 0.0) 
-3.5 




(-1.2 to 3.1) 
-0.1 
(-2.3 to 2.1) 
5.8 -0.3 
(-1.5 to 0.9) 
-0.8 
(-2.2 to 0.7) 
5.9 -0.3 
(-1.6 to 1.0) 
-2.3 
(-3.6 to -1.0) 
House dust mite or grass or cat 
 
29.5 1.2 
(-1.7 to 4.1) 
-2.3 
(-6.0 to 1.4) 
24.1 -0.6 
(-2.7 to 1.6) 
-5.4 
(-7.9 to -2.9) 
19.6 -2.2 
(-4.2 to -0.3) 
-5.4 
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